Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simultaneous TCR and IL-2 agonism selectively enhances epitope-specific CD8 T-cell responses during chronic viral infection.

Journal of virology·2026
Same author

Intralobar pulmonary sequestration and anomalous systemic arterial supply to the basal segment of the lung: A comparative study of clinical features and 3D imaging.

Respiratory investigation·2026
Same author

Selective depletion of virus-specific CD8 T cells from the liver after PD-1 therapy with Fc-intact antibody during chronic infection.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Clinical analysis of the efficacy of bronchial artery embolization with gelatin sponge in our hospital for cryptogenic hemoptysis: a single-center, retrospective, observational study.

BMC pulmonary medicine·2025
Same author

Mitochondrial DNA variants in normal skins: Insights into prevalent pathogenic variants and quality control surveillance.

Mitochondrion·2025
Same author

Intractable Pyopneumothorax due to Lemierre's Syndrome Treated With an Endobronchial Watanabe Spigot (EWS).

Respirology case reports·2025

Related Experiment Video

Updated: Jul 7, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.0K

Harnessing CD8 T cell responses using PD-1-IL-2 combination therapy.

Masao Hashimoto1, Suresh S Ramalingam2, Rafi Ahmed3

  • 1Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA.

Trends in Cancer
|December 21, 2023
PubMed
Summary

Combining interleukin (IL)-2 with programmed cell death (PD)-1 therapy can overcome CD8 T cell exhaustion in cancer. IL-2 signals can reprogram stem-like CD8 T cells, enhancing anti-tumor immunity.

Keywords:
IL-2PD-1T cell exhaustioncancerchronic infectionimmunotherapy

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

326
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.3K

Related Experiment Videos

Last Updated: Jul 7, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.0K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

326
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.3K

Area of Science:

  • Immunology
  • Cancer Biology
  • T cell biology

Background:

  • Programmed cell death (PD)-1 monotherapy faces challenges in overcoming CD8 T cell exhaustion in cancer treatment.
  • Dysfunctional CD8 T cells limit the efficacy of current cancer immunotherapies.
  • Stem-like CD8 T cells expressing PD-1 and T cell factor (TCF)-1 offer a potential target for therapeutic intervention.

Purpose of the Study:

  • To explore the immunological basis for combining interleukin (IL)-2 with PD-1 therapy.
  • To investigate the potential of IL-2 to modulate CD8 T cell exhaustion.
  • To evaluate strategies for generating enhanced effector CD8 T cells from stem-like populations.

Main Methods:

  • Analysis of CD8 T cell states, focusing on PD-1 and TCF-1 expression.
  • Investigating the role of IL-2 signaling in T cell differentiation and exhaustion.
  • Evaluating the efficacy of IL-2 in combination with PD-1 blockade in preclinical models (implied).

Main Results:

  • PD-1+ TCF-1+ stem-like CD8 T cells are not terminally exhausted and can be reprogrammed.
  • Interleukin (IL)-2 signals can alter the differentiation trajectory of these stem-like CD8 T cells.
  • This reprogramming enhances their potential as anti-tumor effectors.

Conclusions:

  • Combining IL-2 with PD-1 therapy provides a rational approach to enhance anti-tumor CD8 T cell responses.
  • Modulating CD8 T cell exhaustion through IL-2 is a key strategy for improving cancer immunotherapy.
  • Careful evaluation of different IL-2-based products is necessary to optimize their impact on anti-tumor CD8 T cells.